



STANFORD
SCHOOL OF MEDICINE



Optical Biopsy of Colon Polyps

2016 PNWGS State-of-the-Art in Gastrointestinal Endoscopy Course

February 27, 2016

Uri Ladabaum, M.D., M.S.

Professor of Medicine

Division of Gastroenterology and Hepatology

Stanford University School of Medicine

Outline

- What is optical biopsy?
- Available modalities
- Applications to colon polyps
- Ready for practice?

Outline

- What is optical biopsy?
- Available modalities
- Applications to colon polyps
- Ready for practice?


Optical biopsy

- Narrower definition: “histology through the endoscope”
 - Confocal laser endomicroscopy (CLE) approaches this the most
- Broader definition: “endoscopic features that *correlate* with histology”
 - e.g. “virtual chromoendoscopy” techniques

Optical biopsy of colon polyps

- What type of polyp is this?
 - Adenoma vs. hyperplastic
 - Sessile serrated
- “High grade” features?
 - High grade dysplasia?
 - Malignancy?
- Extent of involvement / adequacy of resection

Lateral spread: HD white light vs. NBI




Outline

- What is optical biopsy?
- **Available modalities**
- Applications to colon polyps
- Ready for practice?



Optical biopsy

- Narrower definition: “histology through the endoscope”
 - Confocal laser endomicroscopy (CLE) approaches this the most
- Broader definition: “endoscopic features that *correlate* with histology”
 - e.g. “virtual chromoendoscopy” techniques


Confocal laser endomicroscopy



Confocal laser endomicroscopy – probe




Confocal laser endomicroscopy – scope



Confocal laser endomicroscopy

Normal Colon


- Round crypt structures
- Dark goblet cells (arrow)
- Regular, narrow vessels surrounding crypts (block arrow)



Confocal laser endomicroscopy

Hyperplastic Polyp



- Crypts with slit or stellate openings (pits)
- Bright non-thickened, uniform epithelium
- Dark "goblet" cells (thin arrow)
- Small vessels (block arrow)



Confocal laser endomicroscopy

Adenoma


- Irregular or villiform structure (note even "tubular" adenoma may have villiform structure on pCLE)
- Dark, irregularly thickened epithelium
- Decreased goblet cells



Confocal laser endomicroscopy

Adenocarcinoma

- Disorganized villiform or lack of structure
- Dark, irregularly thickened epithelium (thin arrow)
- Dilated vessels (block arrow on H&E)




Optical biopsy

- Narrower definition: “histology through the endoscope”
 - Confocal laser endomicroscopy (CLE) approaches this the most
- Broader definition: “endoscopic features that *correlate* with histology”
 - e.g. “virtual chromoendoscopy” techniques


Electronic Chromoendoscopy

- Selected wavelength tissue-light interaction
- Software post-image processing
 - i-SCAN (PENTAX Endoscopy)
 - Flexible spectral imaging color enhancement (FICE) (Fujinon)
- Endogenous autofluorescence
 - Autofluorescence imaging (AFI) (Olympus)
- Optical filtering of white light
 - Narrow-band imaging (NBI) (Olympus)


Tone enhancement (i-Scan)




FICE




Autofluorescence imaging



Narrow band imaging (NBI)





Narrow band imaging (NBI)




Narrow band imaging (NBI)

- Penetration properties of light \approx wavelength



Tongue: White light vs. NBI



Gono, Clin Endo 2015, 48:476

Outline

- What is optical biopsy?
- Available modalities
- Applications to colon polyps
- Ready for practice?

Optical biopsy of colon polyps

- What type of polyp is this?
 - Adenoma vs. hyperplastic
 - Sessile serrated
- “High grade” features?
 - High grade dysplasia?
 - Malignancy?
- Extent of involvement / adequacy of resection


Adenoma: White light vs. i-SCAN 1 and 2



A





B




C

Adenoma: White light vs. AFI






Adenoma: White light vs. NBI







NBI International Colorectal Endoscopic (NICE) Classification

	Type 1	Type 2
Color	Same or lighter than background	Browner relative to background (verify color arises from vessels)
Vessels	None, or isolated lacy vessels may be present coursing across the lesion	Thick brown vessels surrounding white structures
Surface Pattern	Dark spots surrounded by white	Oval, tubular or branched white structures surrounded by brown vessels
Most likely pathology	Hyperplastic	Adenoma


NBI International Colorectal Endoscopic (NICE) Classification

	Type 1	Type 2
Color		Browner relative to background (verify color arises from vessels)
Vessels		Thick brown vessels surrounding white structures
Surface Pattern		Oval, tubular or branched white structures surrounded by brown vessels
Most likely pathology		Adenoma

NBI International Colorectal Endoscopic (NICE) Classification


	Type 1	Type 2
Color		
Vessels		
Surface Pattern		
Most likely pathology		

Hyperplastic Polyp: NBI vs. White Light




Adenoma: NBI vs. White Light

B



Size	2 mm
Macroscopic classification	Ila
Optical diagnosis (NICE classification)	High confidence Type 2
Pathology	Adenoma

Sessile Serrated Polyp: NBI vs. White Light



ASGE PIVI: real-time endoscopic assessment of histology of diminutive colorectal polyps

- PIVI: “Preservation and Incorporation of Valuable Endoscopic Innovations”

ASGE PIVI: real-time endoscopic assessment of histology of diminutive colorectal polyps

1. In order for polyps ≤ 5 mm to be resected and discarded without pathologic assessment, endoscopic technology (when used with high confidence*) used to determine histology of polyps ≤ 5 mm in size, when combined with the histopathologic assessment of polyps > 5 mm in size, should provide a $\geq 90\%$ agreement in assignment of post-polypectomy surveillance intervals when compared to decisions based on pathology assessment of all identified polyps.

ASGE PIVI: real-time endoscopic assessment of histology of diminutive colorectal polyps

1. In order for polyps ≤ 5 mm to be resected and discarded without pathologic assessment, endoscopic technology (when used with high confidence*) used to determine histology of polyps ≤ 5 mm in size, when combined with the histopathologic assessment of polyps > 5 mm in size, should provide a $\geq 90\%$ agreement in assignment of post-polypectomy surveillance intervals when compared to decisions based on pathology assessment of all identified polyps.

ASGE PIVI: real-time endoscopic assessment of histology of diminutive colorectal polyps

2. In order for a technology to be used to guide the decision to leave suspected rectosigmoid hyperplastic polyps ≤ 5 mm in size in place (without resection), the technology should provide $\geq 90\%$ negative predictive value (when used with high confidence*) for adenomatous histology.

ASGE PIVI: real-time endoscopic assessment of histology of diminutive colorectal polyps

2. In order for a technology to be used to guide the decision to **leave suspected rectosigmoid hyperplastic polyps ≤ 5 mm in size in place** (without resection), the technology should provide **$\geq 90\%$ negative predictive value** (when used with high confidence*) for **adenomatous** histology.

What the PIVI boils down to...

1. If you resect and discard diminutive polyps, get the surveillance recommendation right...
2. If you leave diminutive rectosigmoid polyps in place, make sure they are hyperplastic...


ASGE PIVI: real-time endoscopic assessment of histology of diminutive colorectal polyps

- Supporting considerations:
 - Pathology gold standard is imperfect
 - 85-95% accuracy for adenoma vs. hyperplastic
 - Several factors already affect optimal adherence to surveillance guidelines
 - In this context, some error due to endoscopic histology assessment is acceptable

ASGE PIVI: real-time endoscopic assessment of histology of diminutive colorectal polyps

- Rationale for “resect diminutive and discard” and “diagnose distal hyperplastic and don’t resect”:
 - May reduce cost
 - \$33 million/year in US? (Hassan et al., CGH 2010, 8:865)
 - \$1 billion/year in US? (Kessler et al., Endo 2011, 43:683)
 - May improve patient safety
 - May avoid delay in making surveillance recommendation

Colonoscopy: commercial payments



Ladabaum et al.,
AJG 2014,
109:1513

Colonoscopy: commercial payments for pathology

	Pathology Claim within 7 Days		
	Proportion of all procedures (%)	Mean (s.d.)	Median (10–90th percentiles)
<i>Colonoscopy</i>			
Office	55	\$232 (\$239)	\$148 (\$67–481)
OP Hosp	46	\$352 (\$346)	\$243 (\$90–745)
ASC	47	\$228 (\$215)	\$161 (\$72–450)
Overall	52	\$272 (\$284)	\$185 (\$69–576)

Outline

- What is optical biopsy?
- Available modalities
- Applications to colon polyps
- Ready for practice?

Performance characteristics: Systematic review and meta-analysis

NBI

Performance characteristics: Systematic review and meta-analysis

- NPV for adenoma with NBI:
 - Overall: 91% (95% CI, 88–94%)
 - Academic medical centers: 91.8% (95% CI, 89-94%)
 - Experts 93%: (95% CI, 91-96%)
 - High confidence 93%: (95% CI, 90-96%)

NPV for NBI Optical Biopsy

Study name

	Mean	Lower limit	Upper limit	Total	NPV 90%
East 2008	94.0	89.1	98.9	96	
Rogart 2008	81.0	73.0	89.0	265	
Ignjatovic 2009	82.3	73.8	90.7	213	
Rex 2009	95.4	92.7	98.1	314	
Sano 2009	90.0	82.9	97.1	150	
Van Den Broek 2009	90.2	85.1	95.4	206	
Henry 2010	90.7	84.5	96.9	90	
Lee 2011	92.0	86.7	97.3	125	
Gupta 2012	95.4	93.1	97.7	516	
Hewett_1_2012	99.4	98.8	100.0	201	
Hewett_2_2012	95.0	91.0	99.0	178	
Kuiper_2012	86.6	79.8	93.3	231	
Paggi_2012	86.4	80.9	92.0	399	
Sakamoto_2012	62.2	46.9	77.5	270	
Shahid_2012	75.0	66.1	83.9	103	
Ladabaum_2013	91.4	86.3	96.5	219	
Repici_2013	92.0	88.0	96.0	204	
Singh_2013	100.0	79.9	100.0	40	
Wallace_1_2014	96.0	93.0	99.0	104	
Wallace_2_2014	97.0	95.0	99.0	89	
Random	91.1	88.7	93.6		

ASGE
Tech Cte,
GIE 2015,
81:502

Subgroup by Endoscopist Expertise

Group by Expert	Study name	Statistics for each study		
		Mean	Lower limit	Upper limit
No	Rogart 2008	81.0	73.0	89.0
No	Ignjatovic 2009	82.3	73.8	90.7
No	Van Den Broek 2009	90.2	85.1	95.4
No	Hewett_2_2012	95.0	91.0	99.0
No	Kuiper_2012	86.6	79.8	93.3
No	Sakamoto_2012	62.2	46.9	77.5
No	Ladabaum_2013	91.4	86.3	96.5
Random No		87.3	83.3	91.3
Yes	East 2008	94.0	89.1	98.9
Yes	Rex 2009	95.4	92.7	98.1
Yes	Sano 2009	90.0	82.9	97.1
Yes	Henry 2010	90.7	84.5	96.9
Yes	Lee 2011	92.0	86.7	97.3
Yes	Gupta 2012	95.4	93.1	97.7
Yes	Hewett_1_2012	99.4	98.8	100.0
Yes	Paggi_2012	86.4	80.9	92.0
Yes	Shahid_2012	75.0	66.1	83.9
Yes	Repici_2013	92.0	88.0	96.0
Yes	Singh_2013	100.0	79.9	100.0
Yes	Wallace_1_2014	96.0	93.0	99.0
Yes	Wallace_2_2014	97.0	95.0	99.0
Random Yes		93.2	90.6	95.8

NPV 90%















ASGE
Tech Cte,
GIE 2015,
81:502

Performance characteristics: Systematic review and meta-analysis

- Agreement in surveillance intervals with NBI:
 - Overall: 89% (95% CI, 85-92%)
 - Academic settings: 91% (95% CI, 86-95%)
 - Experienced endoscopists: 92% (95% CI, 88-96%)
 - High confidence 91%: (95% CI, 88-95%)

Agreement with Surveillance Intervals Outcome for NBI Optical Biopsy

Study name

	Mean	Lower limit	Upper limit	Total	90% Agreement
Ignjatovic 2009	95.00	91.06	98.94	82	
Rex 2009	94.12	91.27	96.97	136	
Gupta 2012	86.10	82.91	89.29	410	
Paggi 2012	85.28	80.69	89.87	197	
Kuiper 2012	81.48	72.44	90.52	54	
Coe 2012	70.00	65.32	74.68	317	
Repici 2013	92.00	88.02	95.98	212	
Singh 2013	96.55	94.13	98.97	87	
Ladabaum 2013	79.90	72.51	87.29	1065	
Wallace-1 2014	95.00	93.01	96.99	264	
Wallace-2 2014	94.00	91.01	96.99	258	
Random	88.63	84.57	92.70		

ASGE
Tech Cte,
GIE 2015,
81:502

Subgroup by Endoscopist Expertise

Group by Expert	Study name	Statistics for each study		
		Mean	Lower limit	Upper limit

No	Ignjatovic 2009	95.00	91.06	98.94
No	Kuiper2012	81.48	72.44	90.52
No	Coe2012	70.00	65.32	74.68
No	Ladabaum2013	79.90	72.51	87.29
Random No		81.87	75.50	88.24
Yes	Rex 2009	94.12	91.27	96.97
Yes	Gupta 2012	86.10	82.91	89.29
Yes	Paggi 2012	85.28	80.69	89.87
Yes	Repici 2013	92.00	88.02	95.98
Yes	Singh 2013	96.55	94.13	98.97
Yes	Wallace-1 2014	95.00	93.01	96.99
Yes	Wallace-2 2014	94.00	91.01	96.99
Random Yes		91.99	87.62	96.35

90% Agreement



ASGE
Tech Cte,
GIE 2015,
81:502

Performance characteristics: Systematic review and meta-analysis

i-SCAN

NPV for i-SCAN Optical Biopsy

Group by Expert	Study name	Statistics for each study			NPV 90%
		Mean	Lower limit	Upper limit	
No	Hong_1_2012	67.00	58.71	75.29	□
No	Hong_2_2012	76.20	71.08	81.32	□
No	Chan 2012	70.00	57.15	82.85	□
No	Schachschal 2014	69.00	61.03	76.97	□
Random	No	72.31	68.59	76.04	◆
Yes	Hoffman_1_2010	97.00	94.52	99.48	□
Yes	Hoffman_2_2010	96.50	93.65	99.35	□
Yes	Lee 2011	94.74	90.72	98.76	□
Yes	Piao 2013	93.00	86.26	99.74	□
Random	Yes	96.16	94.39	97.93	◆

ASGE
Tech Cte,
GIE 2015,
81:502

Performance characteristics: Systematic review and meta-analysis

FICE

NPV for FICE Optical Biopsy

Group by Magnification	Study name	Statistics for each study			NPV 90%
		Mean	Lower limit	Upper limit	
No	Pohl 2008	77.00	67.06	86.94	
No	Togashi 2009	76.00	61.59	90.41	
No	Buchner 2010	50.00	31.30	68.70	
No	Longcroft 2011	78.00	72.05	83.95	
Random	No	73.98	66.69	81.28	
Yes	Dos Santos 2010	92.00	85.08	98.92	
Yes	Kim 2011	83.00	79.21	86.79	
Yes	Longcroft 2012	84.00	75.11	92.89	
Yes	Dos Santos 2012	79.00	66.17	91.83	
Random	Yes	85.08	78.93	91.22	

ASGE
Tech Cte,
GIE 2015,
81:502

Optical biopsy of polyps: So, can it be done?

- Test performance = f (technology, operator)
- Optical biopsy *can be done*
- Will most of us be able to do it right?
- Will savings on biopsies be counteracted by inappropriately short surveillance?
- Training?
- Quality assurance?
- What if surveillance recommendations change?

Reality check...

- Surveillance recommendations are evolving...
- Diminutive polyps histology: Much ado about nothing?

US MSTF Surveillance Recommendations

Baseline colonoscopy: most advanced finding(s)	Recommended surveillance interval (y)
No polyps	10
Small (<10 mm) hyperplastic polyps in rectum or sigmoid	10
1–2 small (<10 mm) tubular adenomas	5–10
3–10 tubular adenomas	3
>10 adenomas	<3
One or more tubular adenomas ≥ 10 mm	3
One or more villous adenomas	3
Adenoma with HGD	3

US MSTF Surveillance Recommendations

Baseline colonoscopy: most advanced finding(s)	Recommended surveillance interval (y)
No polyps	10
Small (<10 mm) hyperplastic polyps in rectum or sigmoid	10
1–2 small (<10 mm) tubular adenomas	5–10
3–10 tubular adenomas	3
>10 adenomas	<3
One or more tubular adenomas ≥ 10 mm	3
One or more villous adenomas	3
Adenoma with HGD	3

European Surveillance Recommendations




Fig. 9.1 Recommended surveillance following adenoma removal. (For explanation see Recommendations 9.1 – 9.20 and Sections 9.3 – 9.5)

European Surveillance Recommendations




Fig. 9.1 Recommended surveillance following adenoma removal. (For explanation see Recommendations 9.1 – 9.20 and Sections 9.3 – 9.5)

Requirements for viability in clinical practice

Professional society endorsement

Development of credentialing protocols

Development of validated training tools

Documentation of endoscopic decision making (image storage)

- Medical-legal coverage

- Documentation of adenoma detection rate²

Revision of institutional policies on requirements to submit tissue to pathology²

Reimbursement or other financial incentives for endoscopic determination of pathology

ESGE Guideline: Advanced imaging for colorectal neoplasia




Fig.1 Summary of the recommendations. NPL, nonpolypoid lesion; 0-Ic, lesions with a depressed component; NG-LST, non-granular laterally spreading tumor.

ESGE Guideline: Advanced imaging for colorectal neoplasia




Fig.1 Summary of the recommendations. NPL, nonpolypoid lesion; 0-Ic, lesions with a depressed component; NG-LST, non-granular laterally spreading tumor.

Outline

- What is optical biopsy?
- Available modalities
- Applications to colon polyps
- Ready for practice?

When we look,
what can we see?

I think you'll find
I'm one of the most
empathetic doctors
around.

